Case-Based Roundtable Meetings Spotlight: November 2, 2022

At a live virtual event, Sumit Madan, MD, broke down the use of quadruplet therapies in the frontline setting for patients with multiple myeloma and how to care for patients when they relapse on treatment.

During a Targeted Oncology case-based roundtable event, Daniel Petrylak, MD, discussed with participants the case of a patient with bladder cancer who has lung metastases and significant pulmonary comorbidities.

During a Targeted Oncology case-based roundtable event, Panayiotis S. Savvides, MD, PhD, MPH, discussed with participants their experiences using hedgehog pathway inhibitors and immunotherapy for patients with basal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Kristen M. Pettit, MD, discussed with participants the case of a patient with high-risk primary myelofibrosis and significant cytopenias.

During a Targeted Oncology case-based roundtable event, Yousef Zakharia, MD, discussed new data supporting later-line options for patients with metastatic castration-resistant prostate cancer.

During a Targeted Oncology case-based roundtable event, May Cho, MD, discussed with participants how their practice is impacted by the introduction of trastuzumab deruxtecan for HER2+ gastric cancer.

During a Targeted Oncology case-based roundtable event, Ritu Salani, MD, MBA, discussed multiple studies that back up the use of PARP inhibition as a first-line maintenance therapy for patients with advanced ovarian cancer.

During a Targeted Oncology case-based roundtable event, Yvonne A. Efebara, MD, MPH, discussed the role of triplet and quadruplet systemic therapies for newly diagnosed multiple myeloma and the use of autologous stem cell transplant.

During a Targeted Oncology case-based roundtable event, Pedro Barata, MD, MSc, discussed with participants their approaches to therapy for a patient whose bladder cancer progresses after receiving chemotherapy and immunotherapy.

During a Targeted Oncology case-based roundtable event, Eric S. Nadler, MD, MPP, discussed the data supporting the use of targeted therapy for patients with non–small cell lung cancer and an EGFR exon 20 insertion.